InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
Product | Citation | Year | Journal | Authors | Page |
---|---|---|---|---|---|
LPS-EB (LPS from E. coli O111:B4) | NLRP3 licenses NLRP11 for inflammasome activation in human macrophages. | 2022 | Nat Immunol. | Gangopadhyay A. et al. | DOI: 10.1038/s41590-022-01220-3 |
Pam3CSK4 | NLRP3 licenses NLRP11 for inflammasome activation in human macrophages. | 2022 | Nat Immunol. | Gangopadhyay A. et al. | DOI: 10.1038/s41590-022-01220-3 |
Nigericin | NLRP3 licenses NLRP11 for inflammasome activation in human macrophages. | 2022 | Nat Immunol. | Gangopadhyay A. et al. | DOI: 10.1038/s41590-022-01220-3 |
Alhydrogel® adjuvant 2% | Distinct effects of different adjuvants in the mouse model of allergic airway... | 2022 | Asian Pac J Allergy Immunol. | Shin H.S. et al. | DOI: 10.12932/AP-301219-0729 |
ASC-GFP Reporter Monocytes | Extracellular Inflammasome Particles Are Released After Marathon Running and ... | 2022 | Front Physiol. | Kogel A. et al. | DOI: 10.3389/fphys.2022.866938 |
ODN 1668 - TLR9 ligand | Mitochondrial damage-associated molecular patterns trigger arginase-dependent... | 2022 | Cell Rep. | Westhaver L.P. et al. | DOI: 10.1016/j.celrep.2022.110847 |
Recombinant human IL-18 protein - Bioactive cytokine | Mitochondrial damage-associated molecular patterns trigger arginase-dependent... | 2022 | Cell Rep. | Westhaver L.P. et al. | DOI: 10.1016/j.celrep.2022.110847 |
Recombinant human IL-12 protein - Bioactive cytokine | Mitochondrial damage-associated molecular patterns trigger arginase-dependent... | 2022 | Cell Rep. | Westhaver L.P. et al. | DOI: 10.1016/j.celrep.2022.110847 |
QUANTI-Luc™: Luciferase Detection Reagent | STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robus... | 2022 | Nat Mater. | Dane E.L. et al. | DOI: 10.1038/s41563-022-01251-z |
THP1-Lucia™ ISG Cells | STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robus... | 2022 | Nat Mater. | Dane E.L. et al. | DOI: 10.1038/s41563-022-01251-z |
RAW-Lucia™ ISG Cells | STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robus... | 2022 | Nat Mater. | Dane E.L. et al. | DOI: 10.1038/s41563-022-01251-z |
Normocin® - Antimicrobial Reagent | Human corneal stromal stem cells express anti-fibrotic microRNA-29a and 381-5... | 2022 | J Adv Res. | Yam G.H. et al. | DOI: 10.1016/j.jare.2022.05.008 |
RAW-Blue™ Cells | Human corneal stromal stem cells express anti-fibrotic microRNA-29a and 381-5... | 2022 | J Adv Res. | Yam G.H. et al. | DOI: 10.1016/j.jare.2022.05.008 |
QUANTI-Luc™: Luciferase Detection Reagent | DDX41 is required for cGAS-STING activation against DNA virus infection. | 2022 | Cell Rep. | Singh R.S. et al. | DOI: 10.1016/j.celrep.2022.110856 |
Poly(I:C) LMW | DDX41 is required for cGAS-STING activation against DNA virus infection. | 2022 | Cell Rep. | Singh R.S. et al. | DOI: 10.1016/j.celrep.2022.110856 |
THP1-Dual™ Cells | DDX41 is required for cGAS-STING activation against DNA virus infection. | 2022 | Cell Rep. | Singh R.S. et al. | DOI: 10.1016/j.celrep.2022.110856 |
Poly(dA:dT) | DDX41 is required for cGAS-STING activation against DNA virus infection. | 2022 | Cell Rep. | Singh R.S. et al. | DOI: 10.1016/j.celrep.2022.110856 |
THP1-Dual™ KO-cGAS Cells | DDX41 is required for cGAS-STING activation against DNA virus infection. | 2022 | Cell Rep. | Singh R.S. et al. | DOI: 10.1016/j.celrep.2022.110856 |
ADU-S100 | STING is an intrinsic checkpoint inhibitor that restrains the T H 17 cell pat... | 2022 | Cell Rep. | Damasceno L.E.A. et al. | DOI: 10.1016/j.celrep.2022.110838 |
c-di-GMP | STING is an intrinsic checkpoint inhibitor that restrains the T H 17 cell pat... | 2022 | Cell Rep. | Damasceno L.E.A. et al. | DOI: 10.1016/j.celrep.2022.110838 |